<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500472</url>
  </required_header>
  <id_info>
    <org_study_id>2015NTLS038</org_study_id>
    <nct_id>NCT02500472</nct_id>
  </id_info>
  <brief_title>Investigation of Kava Effects on NNK Metabolism</brief_title>
  <official_title>Investigation of Kava Effects on the Metabolism of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-therapeutic, single-arm pilot clinical trial in adult healthy smokers to
      assess whether kava can alter NNK metabolism in humans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary level (nmol/mL) of total NNAL before and after short-term kava administration</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare urinary level of total NNAL before and after short-term kava administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary level (nmol/mL) of total NNAL before and after short-term kava administration</measure>
    <time_frame>Day 2</time_frame>
    <description>Compare urinary level of total NNAL before and after short-term kava administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary level (nmol/mL) of total NNAL before and after short-term kava administration</measure>
    <time_frame>Day 4</time_frame>
    <description>Compare urinary level of total NNAL before and after short-term kava administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary level (nmol/mL) of total NNAL before and after short-term kava administration</measure>
    <time_frame>Day 5</time_frame>
    <description>Compare urinary level of total NNAL before and after short-term kava administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary level (nmol/mL) of total NNAL before and after short-term kava administration</measure>
    <time_frame>Day 6</time_frame>
    <description>Compare urinary level of total NNAL before and after short-term kava administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary level (nmol/mL) of total NNAL before and after short-term kava administration</measure>
    <time_frame>Day 7</time_frame>
    <description>Compare urinary level of total NNAL before and after short-term kava administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration</measure>
    <time_frame>Day 2</time_frame>
    <description>Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration</measure>
    <time_frame>Day 4</time_frame>
    <description>Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration</measure>
    <time_frame>Day 5</time_frame>
    <description>Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration</measure>
    <time_frame>Day 6</time_frame>
    <description>Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration</measure>
    <time_frame>Day 7</time_frame>
    <description>Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing any particular adverse event</measure>
    <time_frame>Day 4</time_frame>
    <description>Determine the safety of short-term kava administration in healthy smokers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects experiencing any particular adverse event</measure>
    <time_frame>Day 7</time_frame>
    <description>Determine the safety of short-term kava administration in healthy smokers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O6-mG adducts level (fmol) in peripheral blood cells before and after short-term kava administration</measure>
    <time_frame>Day 4</time_frame>
    <description>Quantify O6-mG adducts in peripheral blood cells before and after short-term kava administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O6-mG adducts level (fmol) in peripheral blood cells before and after short-term kava administration</measure>
    <time_frame>Day 7</time_frame>
    <description>Quantify O6-mG adducts in peripheral blood cells before and after short-term kava administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Kava Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Kava</intervention_name>
    <description>3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.</description>
    <arm_group_label>Kava Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ≥ 18 years

          -  Current smoker of ≥ 5 cigarettes daily, determined by self-report

          -  Adequate liver and kidney function, defined as:

               -  Bilirubin, alkaline phosphatase, ALT, and AST within normal limits

               -  Creatinine &lt;1.2

          -  Adequate hemoglobin, defined as a hemoglobin ≥12 mg/dL for men and ≥11 for women.

          -  Ability and willingness to abstain from all medication and dietary supplements for 3
             days prior to kava administration, continuing until a minimum of 7 days after kava
             administration. Topical medications and inhaled medications that do not contain
             steroids are permitted.

          -  Ability and willingness to completely abstain from alcohol consumption for 3 days
             prior to kava administration, continuing until a minimum of 7 days after kava
             administration

          -  Ability to understand the investigational nature of the study and provide informed
             consent

          -  Willingness to take kava supplement as instructed

        Exclusion Criteria:

          -  Known hepatobiliary disease or impairment

          -  History of gastric bypass surgery, gastric banding, bowel resection, malabsorption
             syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that
             may affect the absorption of kava

          -  Chronic medication use that cannot be safely stopped

          -  Use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco,
             cigars, pipes)

          -  Major or chronic medical medical disease, including heart disease, poorly controlled
             diabetes, etc., to be adjudicated by the principal investigator

          -  Women who are pregnant, intend to become pregnant within 3 months of the study
             period, or who are breastfeeding

          -  Current or recent (within 12 months) problems with drug use or alcohol dependence by
             self-report

          -  Antibiotic use within 2 months of study enrollment by self-report

          -  Alcohol dependence, abuse, or history of dependence/abuse by self-report
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Fujioka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naomi Fujioka, MD</last_name>
    <phone>(612) 626-6689</phone>
    <email>fujio002@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justin Eklund</last_name>
    <phone>(612) 624-5949</phone>
    <email>eklun063@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Fujioka, MD</last_name>
      <phone>612-626-6689</phone>
      <email>fujio002@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Alves</last_name>
      <phone>612-625-9175</phone>
      <email>hmalves@umn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>June 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco</keyword>
  <keyword>Smoking</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
